BioSpace News Archive

Drug Development

FDA Greenlights UCB Drug for Severe Form of Epilepsy

UCB’s oral drug for seizures related to Lennox-Gastaut syndrome is now approved in the U.S. for patients ages two years and older.

March 28, 2022
·
3 min read
·
Vanessa Doctor, RN
Business

Axsome Strikes Deal for Narcolepsy Drug with High Growth Potential

The acquisition of Sunosi transforms Axsome into a global commercial business that will support its operations as it moves closer to launching its treatments for depression and migraine.

March 28, 2022
·
3 min read
·
Alex Keown
Policy

U.S. Senate to Take Up Proposed $35 Insulin Cap this Spring

In his State of the Union Address earlier this year, President Joe Biden called for a $35 cap on insulin costs that are provided by insurance programs.

March 28, 2022
·
2 min read
·
Alex Keown
FDA

FDA Limits Use of GSK & Vir’s COVID-19 Antibody Therapy

The FDA amended its EUA for GlaxoSmithKline and Vir Biotechnology’s sotrovimab for COVID-19. The amendment relates specifically to the BA.2 Omicron sub-variant.

March 28, 2022
·
3 min read
·
Mark Terry
BioForest

Sana On Track to Remove Barriers for Cell & Gene Therapy

Before cell and gene therapy can truly become mainstream medicine, the challenges of allogeneic rejection and targeted delivery must be solved. Sana Biotechnology is on the path to do that.

March 28, 2022
·
6 min read
·
Gail Dutton
Drug Development

FDA Documents Released Ahead of Amylyx Adcom Raise Doubts

The FDA released materials for review ahead of Wednesday’s meeting and it appears to paint a picture of insufficient data for approval, noting it is “not exceptionally persuasive.”

March 28, 2022
·
3 min read
·
Mark Terry
Drug Development

Hope Springs Eternal for Inflammatory Disease Treatments at AAD 2022

The 2022 American Academy of Dermatology Annual Meeting saw several milestones for treatment explorations for inflammatory diseases. Here is some of the major news:

March 28, 2022
·
4 min read
·
Vanessa Doctor, RN
Drug Development

Biogen and Ionis Suffer Another Defeat in ALS

Biogen and Ionis Pharmaceuticals announced that their Phase I study of BIIB078 (IONIS-C9Rx) intended for ALS did not meet clinical endpoints, so they will discontinue the program.

March 28, 2022
·
3 min read
·
Hannah Chudleigh
Career Advice

The Best Certifications to Add to Your Resume

Mentioning these certifications in your resume will set you apart from other candidates, clearing your path to your desired role. Learn here how to add certification to resume.

March 28, 2022
·
6 min read
·
Brandi Marcene
Deals

Eagle Announces Acquisition of Acacia in Strategic Good Fit

New Jersey-based Eagle Pharmaceuticals, a company geared towards pharmaceutical hospital sales, has finalized terms to acquire Acacia Pharma Group, PLC.

March 28, 2022
·
2 min read
·
Jazmine Colatriano M.S.